## John W Winkelman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7982032/publications.pdf

Version: 2024-02-01

76326 46799 8,342 142 40 89 citations h-index g-index papers 147 147 147 6255 docs citations citing authors all docs times ranked

#	Article	IF	Citations
1	High national rates of high-dose dopamine agonist prescribing for restless legs syndrome. Sleep, 2022, 45, .	1.1	7
2	A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women. Sleep, 2022, 45, .	1.1	6
3	Restless legs syndrome severity in the National RLS Opioid Registry during the COVID-19 pandemic. Sleep Medicine, 2022, 90, 96-101.	1.6	7
4	Association between subjective–objective discrepancy of sleeping time and health-related quality of life: a community-based polysomnographic study. Psychosomatic Medicine, 2022, Publish Ahead of Print, .	2.0	1
5	Restless Legs Syndrome in X-linked adrenoleukodystrophy. Sleep Medicine, 2022, 91, 31-34.	1.6	5
6	Genetic evidence for a potential causal relationship between insomnia symptoms and suicidal behavior: a Mendelian randomization study. Neuropsychopharmacology, 2022, 47, 1672-1679.	5.4	10
7	How effective are treatment guidelines for augmented RLS?. Sleep, 2022, 45, .	1.1	2
8	Treating Severe Refractory and Augmented Restless Legs Syndrome. Chest, 2022, 162, 693-700.	0.8	8
9	0407 Early Efficacy With Once-Nightly Sodium Oxybate (ON-SXB; FT218): Post-hoc Analyses From REST-ON. Sleep, 2022, 45, A182-A182.	1.1	0
10	0550 Health-Economic Implications of Defined Improvements in Restless Leg Syndrome Severity: A Model-Based Exploratory Analysis based on Prior Publication Data. Sleep, 2022, 45, A242-A243.	1.1	0
11	Baseline and 1-year longitudinal data from the National Restless Legs Syndrome Opioid Registry. Sleep, 2021, 44, .	1.1	15
12	532 Two-Year Longitudinal Data From the National Restless Legs Syndrome Opioid Registry. Sleep, 2021, 44, A209-A209.	1.1	0
13	526 Characteristics of Augmented RLS Patients on Dopamine Agonists at a Tertiary Referral Center: Where Do We Go From Here?. Sleep, 2021, 44, A207-A207.	1.1	0
14	530 Restless Legs Syndrome Prevalence and Severity Among Patients Treated with Buprenorphine and Naloxone for Opioid Use Disorder. Sleep, 2021, 44, A208-A209.	1.1	0
15	Endorsement of European guideline for the diagnosis and treatment of insomnia by the World Sleep Society. Sleep Medicine, 2021, 81, 124-126.	1.6	33
16	The Long-Term Psychiatric and Cardiovascular Morbidity and Mortality of Restless Legs Syndrome and Periodic Limb Movements of Sleep. Sleep Medicine Clinics, 2021, 16, 279-288.	2.6	14
17	The Management of Restless Legs Syndrome: An Updated Algorithm. Mayo Clinic Proceedings, 2021, 96, 1921-1937.	3.0	67
18	We need to do better: A systematic review and meta-analysis of diagnostic test accuracy of restless legs syndrome screening instruments. Sleep Medicine Reviews, 2021, 58, 101461.	8.5	22

#	Article	IF	Citations
19	Consensus Guidelines on Rodent Models of Restless Legs Syndrome. Movement Disorders, 2021, 36, 558-569.	3.9	23
20	Sleep questionnaire copyright fees can benefit research: a response to Chiang and Folz. Sleep, 2021, 44,	1.1	0
21	Sleep and neuropsychiatric illness. Neuropsychopharmacology, 2020, 45, 1-2.	5.4	18
22	How to Identify and Fix Sleep Problems. JAMA Psychiatry, 2020, 77, 99.	11.0	5
23	Realâ€world evidence on the use of benzodiazepine receptor agonists and the risk of venous thromboembolism. Journal of Thrombosis and Haemostasis, 2020, 18, 2878-2888.	3.8	5
24	Sleep and Marijuana Products in 2020. Current Sleep Medicine Reports, 2020, 6, 208-211.	1.4	3
25	Difference in spectral power density of sleep EEG between patients with simple snoring and those with obstructive sleep apnoea. Scientific Reports, 2020, 10, 6135.	3.3	12
26	1H MRS Measurement of Cortical GABA and Glutamate in Primary Insomnia and Major Depressive Disorder: Relationship to Sleep Quality and Depression Severity. Journal of Affective Disorders, 2020, 274, 624-631.	4.1	24
27	Major depressive disorder and insomnia: Exploring a hypothesis of a common neurological basis using waking and sleep-derived heart rate variability. Journal of Psychiatric Research, 2020, 123, 89-94.	3.1	9
28	Topiramate reduces nocturnal eating in sleep-related eating disorder. Sleep, 2020, 43, .	1.1	20
29	Screening for Excessive Daytime Sleepiness and Diagnosing Narcolepsy. Journal of Clinical Psychiatry, 2020, 81, .	2.2	3
30	Recognizing and Treating Excessive Daytime Sleepiness in Patients With Narcolepsy. Journal of Clinical Psychiatry, 2020, 81, .	2.2	0
31	Drug Treatment of Restless Legs Syndrome in Older Adults. Drugs and Aging, 2019, 36, 939-946.	2.7	11
32	Association of Restless Legs Syndrome With Risk of Suicide and Self-harm. JAMA Network Open, 2019, 2, e199966.	5.9	48
33	Individual periodic limb movements with arousal are temporally associated with nonsustained ventricular tachycardia: a case-crossover analysis. Sleep, 2019, 42, .	1.1	12
34	0654 Topiramate Is Efficacious In The Treatment Of Sleep-related Eating Disorder: A Randomized, Double-blind, Placebo-controlled, Parallel Group Study. Sleep, 2019, 42, A261-A261.	1.1	0
35	0668 The National RLS Opioid Registry: Baseline Data on the First 300 Participants. Sleep, 2019, 42, A266-A267.	1.1	0
36	0670 Sleep-Related Event Physiologic Timing for Triggering Nonsustained Ventricular Tachycardia: A Case-crossover Analysis. Sleep, 2019, 42, A267-A268.	1.1	1

#	Article	IF	CITATIONS
37	Reply to: A note on rotigotine for restless legs syndrome after renal transplantation. Movement Disorders, 2019, 34, 152-153.	3.9	0
38	Biological and clinical insights from genetics of insomnia symptoms. Nature Genetics, 2019, 51, 387-393.	21,4	250
39	Short Sleep Duration Is Associated With Increased Serum Homocysteine: Insights From a National Survey. Journal of Clinical Sleep Medicine, 2019, 15, 139-148.	2.6	6
40	Reply to: Safety of dopamine agonists for treating restless legs syndrome. Movement Disorders, 2019, 34, 150-151.	3.9	1
41	Opioid–galanin receptor heteromers mediate the dopaminergic effects of opioids. Journal of Clinical Investigation, 2019, 129, 2730-2744.	8.2	41
42	Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Medicine, 2018, 41, 27-44.	1.6	228
43	The Appropriate Use of Opioids in the Treatment of Refractory Restless Legs Syndrome. Mayo Clinic Proceedings, 2018, 93, 59-67.	3.0	47
44	The Use of Benzodiazepine Receptor Agonists and the Risk of Hospitalization forÂPneumonia. Chest, 2018, 153, 161-171.	0.8	38
45	Respiratory-Related Leg Movements of Sleep Are Associated With Serotonergic Antidepressants But Not Bupropion. Journal of Clinical Sleep Medicine, 2018, 14, 1569-1576.	2.6	7
46	In Reply—Additional Safety Considerations Before Prescribing Opioids to Manage Restless Legs Syndrome. Mayo Clinic Proceedings, 2018, 93, 955-956.	3.0	0
47	Predictors of clinical response in a double-blind placebo controlled crossover trial of gabapentin enacarbil for restless legs syndrome. Sleep Medicine, 2018, 48, 1-7.	1.6	6
48	Treatment of restless legs syndrome: Evidenceâ€based review and implications for clinical practice (Revised 2017) <sup>Â\$</sup> . Movement Disorders, 2018, 33, 1077-1091.	3.9	136
49	Sleep EEG spectral power is correlated with subjective-objective discrepancy of sleep onset latency in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 85, 122-127.	4.8	17
50	Therapeutic Utility of Opioids for Restless Legs Syndrome. Drugs, 2017, 77, 1337-1344.	10.9	7
51	Associations of Incident Cardiovascular Events With Restless Legs Syndrome and Periodic Leg Movements of Sleep in Older Men, for the Outcomes of Sleep Disorders in Older Men Study (MrOS) Tj ETQq1 1	0.7 <b>81</b> 314	rg <b>B</b> \$  Overlo
52	Restless legs syndrome and cardiovascular disease: a research roadmap: A response. Sleep Medicine, 2017, 36, 181.	1.6	3
53	Prevalence of restless legs syndrome during detoxification from alcohol and opioids. Journal of Substance Abuse Treatment, 2017, 73, 35-39.	2.8	22
54	Restless legs syndrome and cardiovascular disease: a research roadmap. Sleep Medicine, 2017, 31, 10-17.	1.6	70

#	Article	IF	CITATIONS
55	Cognitive Behavioral Therapy Using a Mobile Application Synchronizable With Wearable Devices for Insomnia Treatment: A Pilot Study. Journal of Clinical Sleep Medicine, 2017, 13, 633-640.	2.6	42
56	Nocturnal leg cramps: Prevalence and associations with demographics, sleep disturbance symptoms, medical conditions, and cardiometabolic risk factors. PLoS ONE, 2017, 12, e0178465.	2.5	22
57	Obstructive Sleep Apnea as a Complication of Bipolar Disorder and Its Treatment: A Review and Approach to Management. primary care companion for CNS disorders, The, 2017, 19, .	0.6	2
58	Lifestyle Factors and Risk of Restless Legs Syndrome: Prospective Cohort Study. Journal of Clinical Sleep Medicine, 2016, 12, 187-194.	2.6	51
59	Sleep disordered breathing and cardiovascular risk in older patients initiating dialysis in the United States: a retrospective observational study using medicare data. BMC Nephrology, 2016, 17, 16.	1.8	26
60	Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome. Neurology, 2016, 86, 1785-1793.	1.1	38
61	A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation. Sleep Medicine, 2016, 24, 18-23.	1.6	4
62	Probable insomnia is associated with future total energy intake and diet quality in men. American Journal of Clinical Nutrition, 2016, 104, 462-469.	4.7	29
63	Practice guideline summary: Treatment of restless legs syndrome in adults. Neurology, 2016, 87, 2585-2593.	1.1	182
64	Impact of Restless Legs Syndrome on Cardiovascular Autonomic Control. Sleep, 2016, 39, 565-571.	1.1	37
65	Association between sleeping difficulty and type 2 diabetes in women. Diabetologia, 2016, 59, 719-727.	6.3	37
66	Response to Letter to the Editor: "Ferritin deficiency may deteriorate the symptoms of Restless Legs Syndrome― Sleep Medicine, 2016, 22, 105.	1.6	0
67	Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2016, 68, 434-443.	1.9	33
68	Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Medicine, 2016, 21, 1-11.	1.6	242
69	Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study. Current Medical Research and Opinion, 2016, 32, 77-85.	1.9	12
70	Prevalence and associations of respiratory-related leg movements: the MrOS sleep study. Sleep Medicine, 2015, 16, 1236-1244.	1.6	17
71	An Evidence-Based Recommendation for a New Definition of Respiratory-Related Leg Movements. Sleep, 2015, 38, 295-304.	1.1	43
72	Long-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation. CNS Drugs, 2015, 29, 351-357.	5.9	41

#	Article	IF	CITATIONS
73	Restless Legs Syndrome and Psychiatric Disorders. Sleep Medicine Clinics, 2015, 10, 351-357.	2.6	30
74	Restless Legs Syndrome in Patients With Chronic Kidney Disease. Seminars in Nephrology, 2015, 35, 347-358.	1.6	55
75	Genetic associations of periodic limb movements of sleep in the elderly for the MrOS sleep study. Sleep Medicine, 2015, 16, 1360-1365.	1.6	24
76	Valid measures of periodic leg movements (PLMs) during a suggested immobilization test using the PAM-RL leg activity monitors require adjusting detection parameters for noise and signal in each recording. Sleep Medicine, 2014, 15, 132-137.	1.6	8
77	Comparison of Pregabalin with Pramipexole for Restless Legs Syndrome. New England Journal of Medicine, 2014, 370, 621-631.	27.0	189
78	Restless legs syndrome and central nervous system gamma-aminobutyric acid: preliminary associations with periodic limb movements in sleep and restless leg syndrome symptom severity. Sleep Medicine, 2014, 15, 1225-1230.	1.6	46
79	Altered Brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis–Ekbom) Tj ETQq1	1,0,78431 1.6	.4 rgBT /Ove 251
80	Restless legs syndrome/Willis–Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria – history, rationale, description, and significance. Sleep Medicine, 2014, 15, 860-873.	1.6	1,123
81	National Use of Prescription Medications for Insomnia: NHANES 1999-2010. Sleep, 2014, 37, 343-349.	1.1	253
82	Sensory symptoms in restless legs syndrome: the enigma of pain. Sleep Medicine, 2013, 14, 934-942.	1.6	40
83	The long-term treatment of restless legs syndrome/Willis–Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Medicine, 2013, 14, 675-684.	1.6	260
84	Neuroimaging Studies in Insomnia. Current Psychiatry Reports, 2013, 15, 405.	4.5	44
85	Energetic and Cell Membrane Metabolic Products in Patients with Primary Insomnia: A 31-Phosphorus Magnetic Resonance Spectroscopy Study at 4 Tesla. Sleep, 2013, 36, 493-500.	1.1	25
86	Increased Rostral Anterior Cingulate Cortex Volume in Chronic Primary Insomnia. Sleep, 2013, 36, 991-998.	1.1	108
87	Normal Ferritin in a Patient with Iron Deficiency and RLS. Journal of Clinical Sleep Medicine, 2013, 09, 511-513.	2.6	18
88	Reduced Î <sup>3</sup> -Aminobutyric Acid in Occipital and Anterior Cingulate Cortices in Primary Insomnia: a Link to Major Depressive Disorder?. Neuropsychopharmacology, 2012, 37, 1548-1557.	5.4	128
89	Insomnia. Neurologic Clinics, 2012, 30, 1045-1066.	1.8	11
90	Obstructive Sleep Apnea and Severe Mental Illness: Evolution and Consequences. Current Psychiatry Reports, 2012, 14, 503-510.	4.5	28

#	Article	IF	Citations
91	The Role of GABA in Primary Insomnia. Sleep, 2012, 35, 741-742.	1.1	38
92	Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Movement Disorders, 2011, 26, 2065-2072.	3.9	65
93	Sleep-related eating disorder. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 98, 577-585.	1.8	24
94	Rotigotine improves restless legs syndrome: A 6â€month randomized, doubleâ€blind, placeboâ€controlled trial in the United States. Movement Disorders, 2010, 25, 1675-1683.	3.9	102
95	Lack of hippocampal volume differences in primary insomnia and good sleeper controls: An MRI volumetric study at 3Tesla. Sleep Medicine, 2010, 11, 576-582.	1.6	95
96	Clinical and Polysomnographic Characteristics of High Frequency Leg Movements. Journal of Clinical Sleep Medicine, 2010, 06, 431-438.	2.6	20
97	Polysomnographic and Health-related Quality of Life Correlates of Restless Legs Syndrome in the Sleep Heart Health Study. Sleep, 2009, 32, 772-778.	1.1	141
98	Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology, 2008, 70, 35-42.	1.1	375
99	Sleep Disturbance in Bipolar Disorder: Therapeutic Implications. American Journal of Psychiatry, 2008, 165, 830-843.	7.2	217
100	Reduced Brain GABA in Primary Insomnia: Preliminary Data from 4T Proton Magnetic Resonance Spectroscopy (1H-MRS). Sleep, 2008, 31, 1499-1506.	1.1	164
101	Antiepileptics in the Treatment of SleepDisorders. Medical Psychiatry, 2008, , 349-362.	0.2	0
102	Periodic Limb Movements in Sleep â€" Endophenotype for Restless Legs Syndrome?. New England Journal of Medicine, 2007, 357, 703-705.	27.0	65
103	A Better Future for Patients with Restless Legs Syndrome. American Journal of Medicine, 2007, 120, S28-S29.	1.5	11
104	Restless legs syndrome: nonpharmacologic and pharmacologic treatments. Geriatrics, 2007, 62, 13-6.	0.3	2
105	Parasomnias. Psychiatric Clinics of North America, 2006, 29, 969-987.	1.3	18
106	Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Medicine, 2006, 7, 545-552.	1.6	282
107	Heart Rate Response to Respiratory Events With or Without Leg Movements. Sleep, 2006, 29, 553-556.	1.1	35
108	Sleep-Related Eating Disorder and Night Eating Syndrome: Sleep Disorders, Eating Disorders, or Both?. Sleep, 2006, 29, 876-877.	1.1	69

#	Article	IF	Citations
109	Efficacy and Tolerability of Open-Label Topiramate in the Treatment of Sleep-Related Eating Disorder. Journal of Clinical Psychiatry, 2006, 67, 1729-1734.	2.2	67
110	Designing a Sleep Disorders Curriculum for Psychiatry Residents. Harvard Review of Psychiatry, 2005, 13, 54-56.	2.1	4
111	Current Patterns and Future Directions in the Treatment of Insomnia. Annals of Clinical Psychiatry, 2005, 17, 31-40.	0.6	25
112	Antidepressants and Periodic Leg Movements of Sleep. Biological Psychiatry, 2005, 58, 510-514.	1.3	207
113	Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Medicine, 2004, 5, 9-14.	1.6	234
114	Serotonergic Antidepressants are Associated with REM Sleep Without Atonia. Sleep, 2004, 27, 317-321.	1.1	244
115	Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate. Sleep Medicine, 2003, 4, 243-246.	1.6	124
116	Schizophrenia, Obesity, and Obstructive Sleep Apnea. Journal of Clinical Psychiatry, 2001, 62, 8-11.	2.2	262
117	Health status in patients with disturbed sleep and obstructive sleep apnea. Otolaryngology - Head and Neck Surgery, 2000, 122, 542-546.	1.9	17
118	Clinical and Polysomnographic Features of Sleep-Related Eating Disorder. Journal of Clinical Psychiatry, 1998, 59, 14-19.	2.2	158
119	Restless legs syndrome in end-stage renal disease. American Journal of Kidney Diseases, 1996, 28, 372-378.	1.9	338
120	Are Thyroid Function Tests Necessary in Patients With Suspected Sleep Apnea?. Sleep, 1996, 19, 790-793.	1.1	82
121	The function(s) of sleep. , 0, , 59-78.		10
122	Taking a sleep history., 0,, 95-110.		1
123	Circadian rhythm disorders. , 0, , 186-202.		1
124	Principles of insomnia. , 0, , 203-215.		1
125	Treatment of insomnia: pharmacotherapy. , 0, , 216-232.		1
126	Depressive disorders., 0,, 247-265.		2

#	Article	IF	CITATIONS
127	Sleep in anxiety disorders., 0,, 286-297.		2
128	Sleep in developmental disorders., 0,, 371-386.		1
129	Sleep in attention-deficit/hyperactivity disorder (ADHD)., 0,, 343-357.		1
130	Sleep medicine and psychiatry: history and significance., 0,, 1-12.		0
131	Neuroanatomy and neurobiology of sleep and wakefulness. , 0, , 13-35.		2
132	Neurophysiology and neuroimaging of human sleep., 0,, 36-58.		0
133	Sleep-related breathing disorders. , 0, , 111-129.		O
134	Sleep-related movement disorders. , 0, , 130-145.		0
135	Hypersomnias of central origin. , 0, , 146-159.		0
136	Parasomnias. , 0, , 160-185.		0
137	Cognitive behavioral therapy for insomnia. , 0, , 233-246.		0
138	Psychotic disorders., 0,, 298-313.		0
139	Sleep in substance use disorders. , 0, , 314-329.		1
140	Sleep in dementias. , 0, , 330-342.		0
141	Sleep in pediatric mood and anxiety disorders. , 0, , 358-370.		1
142	The future at the sleep–psychiatry interface. , 0, , 387-397.		0